Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry

References

• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. Rev Esp Cardiol. 2014;67:150–151.
   PubMed Web of Science ®Google Scholar
• Vallakati A, Lewis WR. Underuse of anticoagulation in patients with atrial fibrillation. Postgrad Med. 2016;128:191–200.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Freeman JV. Underuse of vitamin K antagonist and direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: a contemporary review. Clin Pharmacol Ther. 2018;104:301–310.
   PubMed Web of Science ®Google Scholar
• Khattak F, Alam MB, Paul TK, et al. Antithrombotic therapy in nonvalvular atrial fibrillation: consensus and challenges. Am J Med Sci. 2018;355:467–476.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69:2475–2484.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–140.
   PubMed Web of Science ®Google Scholar
• Haastrup S, Hellfritzsch M, Rasmussen L, et al. Use of non-vitamin K antagonist oral anticoagulants 2008–2016: a Danish nationwide cohort study. Basic Clin Pharmacol Toxicol. 2018;123:452–463.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145–1153.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124:955–962.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Antz M, Ehlken B, et al. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation – the RELIEF study. Int J Cardiol. 2016;203:882–884.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;32:2047–2053.
   PubMed Web of Science ®Google Scholar
• Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation. PLoS One. 2018;13:e0191592.
   PubMed Web of Science ®Google Scholar
• Therapeutic Positioning Report UT_ACOD/V5/21112016. Criteria and general recommendations for the use of direct oral anticoagulants in the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation [Internet] [cited 2018 May 10]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/criterios-anticoagulantes-orales.pdf
   Google Scholar
• Escobar C, Martí-Almor J, Pérez Cabeza A, et al. Direct oral anticoagulants versus vitamin K antagonists in real-life patients with atrial fibrillation. A systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2019;72:305–316.
   PubMed Web of Science ®Google Scholar
• de la Figuera M, Cinza S, Marín N, et al. Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP Study. Aten Primaria. 2018;50:359–367.
   PubMed Web of Science ®Google Scholar
• de la Figuera M, Prieto MA, Marín N, et al. Differences in the management of patients with atrial fibrillation according to whether primary care or the specialist initiates treatment with direct oral anticoagulants. The SILVER-AP and BRONCE-AP studies. Semergen. 2018;44:323–334.
   PubMedGoogle Scholar
• Ruiz Ortiz M, Muñiz J, Raña Míguez P, et al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20:1577–1583.
   PubMed Web of Science ®Google Scholar
• Mostaza JM, Suárez Fernández C, Castilla Guerra L, et al. Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: the ESPARTA study. J Comp Eff Res. 2018;7:223–232.
   PubMed Web of Science ®Google Scholar
• Contreras Muruaga MD, Vivancos J, Reig G, et al. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Comp Eff Res. 2017;6:303–312.
   PubMed Web of Science ®Google Scholar
• Cerezo-Manchado JJ, Navarro-Almenzar B, Elvira Ruiz G, et al. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke. Future Cardiol. 2018;14:31–37.
   PubMed Web of Science ®Google Scholar
• Inal BB, Oguz O, Emre T, et al. Evaluation of MDRD, Cockcroft–Gault, and CKD-EPI formulas in the estimated glomerular filtration rate. Clin Lab. 2014;60:1685–1694.
   PubMed Web of Science ®Google Scholar
• Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke J Cereb Circ. 2007;38:1655–1711.
   Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581–1598.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692.
   PubMed Web of Science ®Google Scholar
• Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961–972.
   PubMed Web of Science ®Google Scholar
• Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2016;115:939–949.
   PubMed Web of Science ®Google Scholar
• Gullón A, Suárez C, Díez-Manglano J, et al. Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry. Med Clin (Barc). 2017;148:204–210.
   PubMed Web of Science ®Google Scholar
• Suárez Fernández C, Formiga F, Camafort M, et al. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord. 2015;15:143.
   PubMed Web of Science ®Google Scholar
• Mostaza JM, Jiménez MJR, Laiglesia FJR, et al. Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment. J Geriatr Cardiol. 2018;15:268–274.
   PubMedGoogle Scholar
• Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130:138–146.
   PubMed Web of Science ®Google Scholar
• Kumar S, de Lusignan S, McGovern A, et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ. 2018;360:k342.
   PubMed Web of Science ®Google Scholar
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–2394.
   PubMed Web of Science ®Google Scholar
• Gurol ME. Secondary stroke prevention in atrial fibrillation: new insights into an old problem. Stroke. 2018;49:1315–1317.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315–322.
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Fernández-Díaz E, García-García J, et al. Efficacy, safety and tolerability of rivaroxaban for the secondary prevention of stroke in patients with atrial fibrillation in clinical practice. Future Neurol. 2015;10:529–536.
   Web of Science ®Google Scholar
• Yu AYX, Malo S, Svenson LW, et al. Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study. J Am Heart Assoc. 2017;6:pii: e007129.
   Web of Science ®Google Scholar
• Barrios V, Escobar C, Lobos JM, et al. Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study. Semergen. 2017;43:477–485.
   PubMedGoogle Scholar
• Yao X, Shah ND, Sangaralingham LR, et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69:2779–2790.
   PubMed Web of Science ®Google Scholar